Results 201 to 210 of about 192,251 (301)

Re‐Emergent Postural Tremor Without Clinical Resting Tremor in Parkinson's Disease—A Case Report

Movement Disorders Clinical Practice, EarlyView.
Kevin R.E. van den Berg, Rick C. Helmich
wiley   +1 more source

Early Longitudinal Brain Network Changes in Huntington's Disease Before Clinical Motor Onset

Movement Disorders, EarlyView.
Abstract Background Longitudinal studies of seed‐based functional connectivity (SBFC) in young adult Huntington's disease gene‐expanded (HDGE) individuals are rare, and none, to our knowledge, have examined adult cohorts decades from predicted clinical motor diagnosis.
Michela Leocadi, Nicola Z. Hobbs, Mena Farag, Michael J. Murphy, Kate Fayer, Olivia Thackeray, Harry Knights, James B. Rowe, Trevor W. Robbins, Barbara J. Sahakian, Geraint Rees, Rachael I. Scahill, Sarah J. Tabrizi, Christelle Langley   +13 more
wiley   +1 more source

Functional segregation in Parkinson's disease. [PDF]

Sci Adv
Su D, Hanania JU, Pavel A, Bevington C, Fu JF, Matarazzo M, Cheng JK, McKenzie J, Shahinfard E, Vafai N, Dhaliwal S, Miao Q, Seamans J, English C, Chen E, Sossi V, Stoessl AJ.   +16 more
europepmc   +1 more source

Apathy in Lewy Body Disorders: A Position Paper

Movement Disorders, EarlyView.
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky, Lidia Bojtos, Milica G. Kramberger, Elisa Mantovani, Iulia Murasan, Jose‐Alberto Palma, Karolina Poplawska‐Domaszewicz, Anna Sauerbier, Kallol Ray Chaudhuri, Per Odin, Daniel Weintraub, Anette Schrag, Cristian Falup‐Pecorariu   +12 more
wiley   +1 more source

Structural transition in antimicrobial resistance dynamics of <i>Corynebacterium striatum</i>. [PDF]

Infect Dis Model
Lorencz A, Sajerli B, Burián K, Orosz L.   +3 more
europepmc   +1 more source

Spatiotemporal Tau Accumulation and its Clinical Impact on Progressive Supranuclear Palsy: Longitudinal Florzolotau (18F) Positron Emission Tomography

Movement Disorders, EarlyView.
Abstract Background Florzolotau (18F) positron emission tomography (florzolotau PET) enables high‐contrast in vivo detection of four‐repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear.
Yoshikazu Chishiki, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Yuki Momota, Tetsuji Kamada, Chie Seki, Kiwamu Matsuoka, Kosei Hirata, Shin Kurose, Sho Moriguchi, Yuki Komatsu, Hideo Kato, Yasuharu Yamamoto, Yoshikazu Nakano, Shigeki Hirano, Hitoshi Shinotoh, Hitoshi Shimada, Tokahiko Tokuda, Kazunori Kawamura, Ming‐Rong Zhang, Keisuke Takahata, Makoto Higuchi, Hironobu Endo   +27 more
wiley   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Role of alpha-synuclein in the regulation of dopamine neurotransmission in the striatum [PDF]

Chadchankar, Heramb
core  

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Complementary δ2-protocadherin expression delineates parallel basal ganglia circuits in primates. [PDF]

iScience
Hoshina N, Hoshina M, Yamamoto T, Takada M.   +3 more
europepmc   +1 more source